Disrupting HDAC1 condensates in glioblastoma could help to overcome drug resistance

Glioblastoma (GBM) is one of the most common and aggressive primary brain tumors in adults, carrying an extremely poor prognosis and a median overall survival typically less than two years. Temozolomide (TMZ) is currently the only…

Continue Reading


News Source: medicalxpress.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *